PMID- 38151289
OWN - NLM
STAT- MEDLINE
DCOM- 20240105
LR  - 20240106
IS  - 1790-6245 (Electronic)
IS  - 1109-6535 (Print)
IS  - 1109-6535 (Linking)
VI  - 21
IP  - 1
DP  - 2024 Jan-Feb
TI  - Metastatic Lymph Node 64 (MLN64) Expression in Gastric Cancer: The Clinical and 
      Molecular Implications in Drug Resistance.
PG  - 30-40
LID - 10.21873/cgp.20427 [doi]
AB  - BACKGROUND/AIM: Metastatic lymph node 64 (MLN64) is often co-amplified with ERBB2 
      (HER2) and plays a role in the progression of breast and prostate cancer. The 
      present study explored the expression of MLN64 in clinical gastric cancer in 
      association with the ERBB family and its impact on drug resistance in patients. 
      MATERIALS AND METHODS: Two independent gastric cancer cohorts (n=324; n=87) were 
      used to explore the expression profile of MLN64 in conjunction with ERBB family 
      members in clinical gastric cancer and its association with neoadjuvant 
      chemotherapy responses. Gastric cancer AGS and HCG27 cells with MLN64 knockdown 
      were generated to determine the function of MLN64 in cell behavioural changes. 
      RESULTS: Gastric tumor tissues expressed significantly higher levels of MLN64 
      compared with normal tissues (p<0.01); however, MLN64 alone was a weak prognostic 
      indicator. An integrated co-expression of MLN64, ERBB4, and NRG4 was a 
      significant factor in assessing overall survival in both cohorts. MLN64 was a 
      profound indicator of patient response to neoadjuvant chemotherapy. In vitro 
      studies indicated a significant contribution of MLN64 to the response of gastric 
      cancer cells to chemodrugs and Her-2 inhibitors. MLN64 knockdown also contributed 
      to the adhesion and migration and suggested a possible mechanism mediated by the 
      interaction between MLN64 and ERBBs. CONCLUSION: MLN64 is an indicator of patient 
      response to neoadjuvant chemotherapy in gastric cancer. Together with the 
      expression pattern of ERBB4, MLN64 is a poor prognostic factor for patients with 
      gastric cancer.
CI  - Copyright (c) 2024, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Li, Amber Xinyu
AU  - Li AX
AD  - Cardiff University School of Medicine, Cardiff, U.K.
FAU - Zeng, Jimmy Jianyuan
AU  - Zeng JJ
AD  - Cardiff University School of Medicine, Cardiff, U.K.
FAU - Khan, Elyas
AU  - Khan E
AD  - Karmanos Cancer Institute, Department of Oncology, School of Medicine, Wayne 
      State University, Detroit, MI, U.S.A.
FAU - Dou, Q Ping
AU  - Dou QP
AD  - Cardiff University School of Medicine, Cardiff, U.K.
AD  - Karmanos Cancer Institute, Department of Oncology, School of Medicine, Wayne 
      State University, Detroit, MI, U.S.A.
FAU - Zhuang, Xinguo
AU  - Zhuang X
AD  - Cardiff University School of Medicine, Cardiff, U.K.
FAU - Ji, Edison Ke
AU  - Ji EK
AD  - Gastrointestinal Cancer Centre, Peking University Cancer Hospital, Beijing, P.R. 
      China.
FAU - Ruge, Fiona
AU  - Ruge F
AD  - Cardiff University School of Medicine, Cardiff, U.K.
FAU - Martin, Tracey A
AU  - Martin TA
AD  - Cardiff University School of Medicine, Cardiff, U.K.
FAU - Jia, Shuqin
AU  - Jia S
AD  - Gastrointestinal Cancer Centre, Peking University Cancer Hospital, Beijing, P.R. 
      China.
FAU - Jiang, Wen G
AU  - Jiang WG
AD  - Cardiff University School of Medicine, Cardiff, U.K.; jiangw@cardiff.ac.uk.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Cancer Genomics Proteomics
JT  - Cancer genomics & proteomics
JID - 101188791
RN  - 0 (STARD3 protein, human)
SB  - IM
MH  - Humans
MH  - Male
MH  - Drug Resistance
MH  - Lymph Nodes
MH  - Prognosis
MH  - *Stomach Neoplasms/drug therapy/genetics
PMC - PMC10756345
OTO - NOTNLM
OT  - ERBB4
OT  - MLN64
OT  - NRG
OT  - STARD3
OT  - drug response
OT  - gastric cancer
OT  - prognosis
OT  - signalling
COIS- The Authors declare no conflicts of interest in relation to this study.
EDAT- 2023/12/28 00:42
MHDA- 2023/12/29 06:43
PMCR- 2024/01/03
CRDT- 2023/12/27 20:53
PHST- 2023/08/30 00:00 [received]
PHST- 2023/10/10 00:00 [revised]
PHST- 2023/10/11 00:00 [accepted]
PHST- 2023/12/29 06:43 [medline]
PHST- 2023/12/28 00:42 [pubmed]
PHST- 2023/12/27 20:53 [entrez]
PHST- 2024/01/03 00:00 [pmc-release]
AID - 21/1/30 [pii]
AID - 10.21873/cgp.20427 [doi]
PST - ppublish
SO  - Cancer Genomics Proteomics. 2024 Jan-Feb;21(1):30-40. doi: 10.21873/cgp.20427.